NCT07637929Not yet recruiting
Non-Interventional Study of Puzol-cel for CD19-Positive Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia
Non-Interventional Study of Puzolcabtagene Autoleucel Injection for CD19-Positive Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia
Source: ClinicalTrials.gov · Last updated 10 Jun 2026
Brief summary (registry, in English)
Establishing real-world data of Chinese patients with CD19-positive relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL) treated with Puzolcabtagene Autoleucel Injection to evaluate its effectiveness.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 200 (estimated)
- First submitted
- 22 May 2026
- Start date
- Jun 2026
- Primary completion date
- Dec 2032
- Lead sponsor
- Chongqing Precision Biotech Co., Ltd
- NCT number
- NCT07637929
What you commit to
- Study type: Observational
- Planned participants: 200
- From Jun 2026 to the primary completion date, Dec 2032
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Patients who test positive for hepatitis C virus (HCV), human immunodeficiency virus (HIV), and Treponema pallidum (TP).
Who the study is looking for
- Patients with r/r B-ALL who receive treatment with Pucicelant Injection at a research center commercially certified by Chongqing Precision Biotech in China, and whose bone marrow tumor cells are confirmed to express CD19 by flow cytometry
- Patients with essentially normal function of vital organs
- Patients who voluntarily participate in this study and sign the informed consent form. For patients under 18 years of age, informed consent must also be obtained from their legal guardians
Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.